Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 17/20 | 0.65 |
| ▸ | ECE1 | P42892 | 1/20 | 0.59 |
| ▸ | GLP1R | P43220 | 1/20 | 0.59 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.59 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30571041 | 0.97 | KISS1R (0.62) | KISS1RECE1GLP1RMUS81NPBWR1 | |
| SCHEMBL30130560 | 0.97 | KISS1R (0.62) | KISS1RECE1GLP1RMUS81NPBWR1 | |
| SCHEMBL30130562 | 0.97 | KISS1R (0.62) | KISS1RECE1GLP1RMUS81NPBWR1 | |
| SCHEMBL30130543 | 0.97 | KISS1R (0.62) | KISS1RECE1GLP1RMUS81NPBWR1 | |
| SCHEMBL30130579 | 0.97 | KISS1R (0.62) | KISS1RECE1GLP1RMUS81NPBWR1 | |
| SCHEMBL30130528 | 0.95 | NPBWR1 (0.62) | KISS1RECE1GLP1RMUS81NPBWR1 | |
| SCHEMBL30130547 | 0.95 | KISS1R (0.57) | KISS1RECE1GLP1RMUS81 | |
| SCHEMBL30130555 | 0.95 | KISS1R (0.57) | KISS1RECE1GLP1RMUS81 | |
| SCHEMBL30092943 | 0.94 | KISS1R (0.56) | KISS1RECE1GLP1RMUS81 | |
| SCHEMBL30607735 | 0.94 | KISS1R (0.61) | KISS1RECE1GLP1RMUS81NPBWR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287044-A1 | NOVEL ANTIBACTERIAL PEPTIDE AND USE THEREOF | ANYGEN CO., LTD. (KR) | 2023-09-14 | — | — | US | claimed |
| EP-4129064-A1 | NOVEL ANTIBACTERIAL PEPTIDE AND USE THEREOF | Anygen Co., Ltd. (KR) | 2023-02-08 | — | — | EP | claimed |
| US-20230287044-A1 | NOVEL ANTIBACTERIAL PEPTIDE AND USE THEREOF | ANYGEN CO., LTD. (KR) | 2023-09-14 | — | — | US | disclosed |
| EP-4129064-A1 | NOVEL ANTIBACTERIAL PEPTIDE AND USE THEREOF | Anygen Co., Ltd. (KR) | 2023-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287044-A1 | NOVEL ANTIBACTERIAL PEPTIDE AND USE THEREOF | VIP, CUTA, LNPEP | KISS1R 1140/4885ECE1 2913/4885GLP1R 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.